Myriad Genetics Inc 8-K Filing
Ticker: MYGN · Form: 8-K · Filed: Nov 3, 2025 · CIK: 899923
| Field | Detail |
|---|---|
| Company | Myriad Genetics Inc (MYGN) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Myriad Genetics Inc (ticker: MYGN) to the SEC on Nov 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar).
How long is this filing?
Myriad Genetics Inc's 8-K filing is 2 pages with approximately 655 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 11 · Accepted 2025-11-03 16:07:57
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
Filing Documents
- mygn-20251103.htm (8-K) — 30KB
- ex991mygn-xearningsrelease.htm (EX-99.1) — 486KB
- imagea.jpg (GRAPHIC) — 33KB
- 0000899923-25-000103.txt ( ) — 738KB
- mygn-20251103.xsd (EX-101.SCH) — 2KB
- mygn-20251103_def.xml (EX-101.DEF) — 14KB
- mygn-20251103_lab.xml (EX-101.LAB) — 25KB
- mygn-20251103_pre.xml (EX-101.PRE) — 15KB
- mygn-20251103_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition. On November 3, 2025 Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2025. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these forward-looking statements.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Earnings release dated November 3, 2025 for the three months ended September 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Current Report on Form 8-K. Limitation on Incorporation by Reference . In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: November 3, 2025 /s/ Benjamin R. Wheeler Benjamin R. Wheeler Chief Financial Officer